Steven E. Nissen

机构：Cleveland Clinic, Esperion Therapeutics (United States), Cleveland Foundation, Cleveland Clinic Lerner College of Medicine, Center for Clinical Research (United States) · ORCID：0000-0002-7231-6464

发表论文 899 篇 · 总被引 90347 次 · h-index 121

代表论文

• Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (2025 · New England Journal of Medicine · 被引 175)
• Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (2025 · New England Journal of Medicine · 被引 73)
• Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 (2025 · New England Journal of Medicine · 被引 65)
• Macrovascular and microvascular outcomes of metabolic surgery versus GLP-1 receptor agonists in patients with diabetes and obesity (2025 · Nature Medicine · 被引 19)
• Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND (2026 · Diabetes Care · 被引 10)
• Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial (2026 · Nature Medicine · 被引 10)